Researchers from Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center (BMC) reviewed cancer ...

The FDA has started a priority review of GSK's gepotidacin, which could become the first in a new class of oral antibiotics for uncomplicated urinary tract infections (uUTIs) in over 20 years. The US ...

The oncology landscape is evolving, with a marked rise in cancer incidence among young adults globally. This challenges the traditional view of cancer as primarily an ailment of the elderly. The ...

Long-term considerations: While short-term forecasting remains a priority, forecasters also keep an eye on medium and ...

According to MeiraGTx, AAV-GAD is designed to reprogramme dysfunctional circuits in the Parkinson's brain through the local production of GABA, a neurotransmitter that can help restore more normal ...

Pfizer is already active in the protein degrader area, having partnered with Arvinas in a $2 billion-plus deal signed in 2021 focusing on vepdegestrant (ARV-471), an orally active selective oestrogen ...

The Mandl team was originally employed by Novartis, but GSK acquired rights to their work and intellectual property when it acquired Novartis' global vaccine business in 2015. Only by tapping into ...

mRNA vaccines, pivotal in the fight against COVID-19, are now emerging as a promising innovation in cancer treatment. As ...

To encourage the uptake of complex therapies in clinical practice, brand teams must ensure they use data-driven insights to ...

Germany has become the debut market for LEO Pharma's Anzupgo, the first topical treatment specifically approved for chronic ...

It is Transgene's second most advanced neoantigen immunotherapy programme after TG4050 for head and neck cancer, which is in ...

The proposal, unveiled at the government's International Investment Summit today is headlined by the creation of a UK biotech ...